Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2009210 | 0.92 | LMNA (0.50) | GRM5LMNAL3MBTL1FFAR1KMT2A | |
| SCHEMBL2013745 | 0.91 | GRM5 (0.53) | GRM5LMNAL3MBTL1FFAR1 | |
| SCHEMBL2010073 | 0.87 | GRM5 (0.43) | GRM5LMNAL3MBTL1FFAR1 | |
| SCHEMBL2013401 | 0.86 | GRM5 (0.66) | GRM5LMNAFFAR1 | |
| SCHEMBL2008101 | 0.86 | GRM5 (0.65) | GRM5FFAR1 | |
| SCHEMBL2015726 | 0.86 | GRM5 (0.55) | GRM5FFAR1 | |
| SCHEMBL2009110 | 0.85 | GRM5 (0.49) | GRM5LMNAL3MBTL1FFAR1 | |
| SCHEMBL2013082 | 0.84 | GRM5 (0.54) | GRM5FFAR1CHRNB2CHRNA4AR | |
| SCHEMBL2013405 | 0.84 | GRM5 (0.50) | GRM5FFAR1 | |
| SCHEMBL2013751 | 0.82 | GRM5 (0.55) | GRM5FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831193-B1 | IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | EP | claimed |
| US-7452909-B2 | Imidazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-11-18 | — | — | US | claimed |
| EP-1831193-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-12 | — | — | EP | claimed |
| WO-2005023795-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | claimed |
| US-20050054686-A1 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. | 2005-03-10 | — | — | US | claimed |
| US-7964620-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-1831193-B1 | IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20090018171-A1 | IMIDAZOLE DERIVATIVES | BUETTELMANN BERND | 2009-01-15 | — | — | US | disclosed |
| US-7452909-B2 | Imidazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-11-18 | — | — | US | disclosed |
| EP-1831193-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| WO-2005023795-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054686-A1 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054686-A1 | Imidazole derivatives | CHRM2, CHRM1, ARG1 | GRM5 758/4885LMNA 3620/4885L3MBTL1 4023/4885 |
| US-20090018171-A1 | IMIDAZOLE DERIVATIVES | CHRM2, CHRM1, ARG1 | GRM5 758/4885LMNA 3620/4885L3MBTL1 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.